Equillium, Inc. Secures $50M to Advance Itolizumab and Revolutionize Autoimmune Disease Treatment

Equillium, Inc. is proud to announce a significant milestone as it successfully raised $50,000,000 in its latest funding round. This latest capital raise will drive the company’s ambitious mission: to dramatically improve the lives of patients suffering from severe autoimmune and inflammatory diseases that have long been burdened by high unmet medical needs. As a clinical-stage biotechnology company, Equillium leverages a deep understanding of immunobiology to develop groundbreaking treatments designed to restore balance to an overactive immune system. This innovative approach is at the core of its vision to ultimately restore the balance of life for those affected. Central to this initiative is Equillium’s lead product candidate, itolizumab—a first-in-class monoclonal antibody targeting the CD6-ALCAM signaling pathway. This pathway plays a pivotal role in the activation and trafficking of pathogenic effector T cells, which are known for driving inflammation across a range of debilitating conditions. With a pipeline focused on advancing itolizumab as a best-in-class remedy, Equillium is targeting a spectrum of severe immuno-inflammatory disorders, including acute graft-versus-host disease, SLE/lupus nephritis, and uncontrolled asthma. The newly raised funds will be strategically invested in accelerating clinical development, refining research strategies, and ultimately bringing these promising therapies to the market. This investment not only fuels the company’s cutting-edge research but also reinforces its commitment to addressing some of the most critical challenges in modern medicine. With a robust development plan and clear milestones ahead, Equillium is positioned to transform the therapeutic landscape for patients in need, marking a new era of hope and innovation in immunomodulatory therapies.